Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception

January 19, 2017
With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia. Speaking at Biotech Showcase, List explained to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how he is also looking for assets designed to prevent, cure or even intercept the progression of key diseases such as obesity and NASH.
Previous Video
Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017
Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017

An increased focus on the need to access and develop truly transformational medicines was a key theme in th...

Next Video
Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America
Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America

As Johnson & Johnson announced the establishment of its eighth JLABS facility, in collaboration with New Yo...